-
2
-
-
14244267601
-
Psoriasis: Epidemiology, clinical features, and quality of life
-
Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl 2): ii18-23.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.SUPPL. 2
-
-
Langley, R.G.1
Krueger, G.G.2
Griffiths, C.E.3
-
3
-
-
20444497652
-
Psoriasis - Recent advances in understanding its pathogenesis and treatment
-
DOI 10.1016/j.jaad.2005.04.035, PII S0190962205013137, New Strategies for Optimizing the Treatment of Inflamatory Dermatoses with Topical Corticosteroids in an Era of Costisosteroids-Sparing
-
Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53(1 Suppl 1): S94-100. (Pubitemid 40828186)
-
(2005)
Journal of the American Academy of Dermatology
, vol.53
, Issue.1 SUPPL.
-
-
Krueger, G.1
Ellis, C.N.2
-
4
-
-
65349134699
-
Psoriasis bench to bedside: Genetics meets immunology
-
Nair RP, Ding J, Duffin KC, et al. Psoriasis bench to bedside: Genetics meets immunology. Arch Dermatol 2009; 145(4): 462-464
-
(2009)
Arch Dermatol
, vol.145
, Issue.4
, pp. 462-464
-
-
Nair, R.P.1
Ding, J.2
Duffin, K.C.3
-
5
-
-
14244258610
-
Psoriasis pathophysiology: Current concepts of pathogenesis
-
DOI 10.1136/ard.2004.031120
-
Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 2005; 64(Suppl 2): ii30-6. (Pubitemid 40288517)
-
(2005)
Annals of the Rheumatic Diseases
, vol.64
, Issue.SUPPL. 2
-
-
Krueger, J.G.1
Bowcock, A.2
-
6
-
-
33846238954
-
Psoriasis: A possible risk factor for development of coronary artery calcification
-
DOI 10.1111/j.1365-2133.2006.07562.x
-
Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156(2): 271-276 (Pubitemid 46095954)
-
(2007)
British Journal of Dermatology
, vol.156
, Issue.2
, pp. 271-276
-
-
Ludwig, R.J.1
Herzog, C.2
Rostock, A.3
Ochsendorf, F.R.4
Zollner, T.M.5
Thaci, D.6
Kaufmann, R.7
Vogl, T.J.8
Boehncke, W.-H.9
-
7
-
-
48849107322
-
Psoriasis, metabolic syndrome and its components
-
Ortonne JP. Psoriasis, metabolic syndrome and its components. Ann Dermatol Vénéréol 2008; 135(Suppl 4): 235-242
-
(2008)
Ann Dermatol Vénéréol
, vol.135
, Issue.SUPPL. 4
, pp. 235-242
-
-
Ortonne, J.P.1
-
8
-
-
58049198305
-
Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome
-
Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144(12): 1571-1575
-
(2008)
Arch Dermatol
, vol.144
, Issue.12
, pp. 1571-1575
-
-
Chen, Y.J.1
Wu, C.Y.2
Shen, J.L.3
-
9
-
-
54249136408
-
Comedication related to comorbidities: A study in 1203 hospitalized patients with severe psoriasis
-
Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: A study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008; 159(5): 1116-1123
-
(2008)
Br J Dermatol
, vol.159
, Issue.5
, pp. 1116-1123
-
-
Gerdes, S.1
Zahl, V.A.2
Knopf, H.3
-
10
-
-
0033044964
-
The pathogenesis of psoriasis: Immunological facts and speculations
-
Bos JD, de Rie MA. The pathogenesis of psoriasis: Immunological facts and speculations. Immunol Today 1999; 20(1): 40-46
-
(1999)
Immunol Today
, vol.20
, Issue.1
, pp. 40-46
-
-
Bos, J.D.1
De Rie, M.A.2
-
11
-
-
25844505509
-
The genetics of psoriasis and autoimmunity
-
Bowcock AM. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet 2005; 6: 93-122.
-
(2005)
Annu Rev Genomics Hum Genet
, vol.6
, pp. 93-122
-
-
Bowcock, A.M.1
-
12
-
-
33750282677
-
The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation
-
Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006; 18(6): 670-675
-
(2006)
Curr Opin Immunol
, vol.18
, Issue.6
, pp. 670-675
-
-
Kikly, K.1
Liu, L.2
Na, S.3
Sedgwick, J.D.4
-
13
-
-
0347285359
-
Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris
-
DOI 10.1084/jem.20030451
-
Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199(1): 125-130 (Pubitemid 38076484)
-
(2004)
Journal of Experimental Medicine
, vol.199
, Issue.1
, pp. 125-130
-
-
Lee, E.1
Trepicchio, W.L.2
Oestreicher, J.L.3
Pittman, D.4
Wang, F.5
Chamian, F.6
Dhodapkar, M.7
Krueger, J.G.8
-
14
-
-
36049052516
-
Interleukin-12, interleukin-23, and psoriasis: Current prospects
-
Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: Current prospects. J Am Acad Dermatol 2007; 57(6): 1059-1068
-
(2007)
J Am Acad Dermatol
, vol.57
, Issue.6
, pp. 1059-1068
-
-
Torti, D.C.1
Feldman, S.R.2
-
15
-
-
31144441631
-
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin
-
Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 2006; 176(3): 1908-1915
-
(2006)
J Immunol
, vol.176
, Issue.3
, pp. 1908-1915
-
-
Piskin, G.1
Sylva-Steenland, R.M.2
Bos, J.D.3
Teunissen, M.B.4
-
16
-
-
33846906224
-
H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
-
DOI 10.1038/nature05505, PII NATURE05505
-
Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445(7128): 648-651 (Pubitemid 46232884)
-
(2007)
Nature
, vol.445
, Issue.7128
, pp. 648-651
-
-
Zheng, Y.1
Danilenko, D.M.2
Valdez, P.3
Kasman, I.4
Eastham-Anderson, J.5
Wu, J.6
Ouyang, W.7
-
17
-
-
0037449737
-
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
-
DOI 10.1074/jbc.M207577200
-
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 + T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278(3): 1910-1914 (Pubitemid 36801431)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.3
, pp. 1910-1914
-
-
Aggarwal, S.1
Ghilardi, N.2
Xie, M.-H.3
De Sauvage, F.J.4
Gurney, A.L.5
-
18
-
-
0033638507
-
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
-
Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13(5): 715-725
-
(2000)
Immunity
, vol.13
, Issue.5
, pp. 715-725
-
-
Oppmann, B.1
Lesley, R.2
Blom, B.3
-
19
-
-
33847757147
-
Cracking the cytokine code in psoriasis
-
Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13(3): 242-244
-
(2007)
Nat Med
, vol.13
, Issue.3
, pp. 242-244
-
-
Nickoloff, B.J.1
-
21
-
-
33845337658
-
Genomics and proteomics: Emerging technologies in clinical cancer research
-
DOI 10.1016/j.critrevonc.2006.06.005, PII S1040842806001090
-
Chung CH, Levy S, Chaurand P, Carbone DP. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol 2006; 61(1): 1-25. (Pubitemid 44880146)
-
(2007)
Critical Reviews in Oncology/Hematology
, vol.61
, Issue.1
, pp. 1-25
-
-
Chung, C.H.1
Levy, S.2
Chaurand, P.3
Carbone, D.P.4
-
22
-
-
33747081620
-
Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: A potential breakthrough diagnostic and individualized therapy-design tool
-
DOI 10.1111/j.1365-3083.2006.01802.x
-
Centola M, Frank MB, Bolstad AI, et al. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: A potential breakthrough diagnostic and individualized therapy-design tool. Scand J Immunol 2006; 64(3): 236-242 (Pubitemid 44215113)
-
(2006)
Scandinavian Journal of Immunology
, vol.64
, Issue.3
, pp. 236-242
-
-
Centola, M.1
Frank, M.B.2
Bolstad, A.I.3
Alex, P.4
Szanto, A.5
Zeher, M.6
Hjelmervik, T.O.7
Jonsson, R.8
Nakken, B.9
Szegedi, G.10
Szodoray, P.11
-
23
-
-
31444431754
-
Reliability and reproducibility issues in DNA microarray measurements
-
DOI 10.1016/j.tig.2005.12.005, PII S0168952505003598
-
Draghici S, Khatri P, Eklund AC, et al. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006; 22(2): 101-109 (Pubitemid 43152029)
-
(2006)
Trends in Genetics
, vol.22
, Issue.2
, pp. 101-109
-
-
Draghici, S.1
Khatri, P.2
Eklund, A.C.3
Szallasi, Z.4
-
24
-
-
0035880456
-
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies
-
Bowcock AM, Shannon W, Du F, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001; 10(17): 1793-1805 (Pubitemid 32899097)
-
(2001)
Human Molecular Genetics
, vol.10
, Issue.17
, pp. 1793-1805
-
-
Bowcock, A.M.1
Shannon, W.2
Du, F.3
Duncan, J.4
Cao, K.5
Aftergut, K.6
Catier, J.7
Fernandez-Vina, M.A.8
Menter, A.9
-
25
-
-
0035756813
-
Molecular classification of psoriasis diseaseassociated genes through pharmacogenomic expression profiling
-
Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1(4): 272-287 (Pubitemid 33756652)
-
(2001)
Pharmacogenomics Journal
, vol.1
, Issue.4
, pp. 272-287
-
-
Oestreicher, J.L.1
Walters, I.B.2
Kikuchi, T.3
Gilleaudeau, P.4
-
26
-
-
20244378241
-
Gene expression profiles in psoriasis: Analysis of impact of body site location and clinical severity
-
DOI 10.1111/j.1365-2133.2005.06384.x
-
Quekenborn-Trinquet V, Fogel P, Aldana-Jammayrac O, et al. Gene expression profiles in psoriasis: Analysis of impact of body site location and clinical severity. Br J Dermatol 2005; 152(3): 489-504. (Pubitemid 40547123)
-
(2005)
British Journal of Dermatology
, vol.152
, Issue.3
, pp. 489-504
-
-
Quekenborn-Trinquet, V.1
Fogel, P.2
Aldana-Jammayrac, O.3
Ancian, P.4
Demarchez, M.5
Rossio, P.6
Richards, H.L.7
Kirby, B.8
Nguyen, C.9
Voegel, J.J.10
Griffiths, C.E.M.11
-
27
-
-
0037453146
-
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array
-
Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13(1): 69-78. (Pubitemid 37129170)
-
(2003)
Physiological Genomics
, vol.13
, pp. 69-78
-
-
Zhou, X.1
Krueger, J.G.2
Kao, M.-C.J.3
Lee, E.4
Du, F.5
Menter, A.6
Wong, W.H.7
Bowcock, A.M.8
-
28
-
-
22544480310
-
Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules
-
Koczan D, Guthke R, Thiesen HJ, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15(4): 251-257 (Pubitemid 41020851)
-
(2005)
European Journal of Dermatology
, vol.15
, Issue.4
, pp. 251-257
-
-
Koczan, D.1
Guthke, R.2
Thiesen, H.-J.3
Ibrahim, S.M.4
Kundt, G.5
Krentz, H.6
Gross, G.7
Kunz, M.8
-
29
-
-
4644309388
-
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment
-
Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51(4): 563-569
-
(2004)
J Am Acad Dermatol
, vol.51
, Issue.4
, pp. 563-569
-
-
Langley, R.G.1
Ellis, C.N.2
-
30
-
-
62049084468
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
-
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60(4): 643-659
-
(2009)
J Am Acad Dermatol
, vol.60
, Issue.4
, pp. 643-659
-
-
Menter, A.1
Korman, N.J.2
Elmets, C.A.3
-
31
-
-
68949149916
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
-
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61(3): 451-485
-
(2009)
J Am Acad Dermatol
, vol.61
, Issue.3
, pp. 451-485
-
-
Menter, A.1
Korman, N.J.2
Elmets, C.A.3
-
32
-
-
0036344554
-
Clinical features of psoriatic arthritis
-
Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care 2002; 8(6 Suppl): S160-70.
-
(2002)
Am J Manag Care
, vol.8
, Issue.6 SUPPL.
-
-
Krueger, G.G.1
-
33
-
-
65349091931
-
Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial
-
Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145(4): 387-393
-
(2009)
Arch Dermatol
, vol.145
, Issue.4
, pp. 387-393
-
-
Mittal, R.1
Malhotra, S.2
Pandhi, P.3
Kaur, I.4
Dogra, S.5
-
34
-
-
56549084244
-
Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis
-
Lin YK, Chang CJ, Chang YC, Wong WR, Chang SC, Pang JH. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol 2008; 144(11): 1457-1464
-
(2008)
Arch Dermatol
, vol.144
, Issue.11
, pp. 1457-1464
-
-
Lin, Y.K.1
Chang, C.J.2
Chang, Y.C.3
Wong, W.R.4
Chang, S.C.5
Pang, J.H.6
-
35
-
-
0024314554
-
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
-
Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2(8657): 244-247 (Pubitemid 19180612)
-
(1989)
Lancet
, vol.2
, Issue.8657
, pp. 244-247
-
-
Brennan, F.M.1
Jackson, A.2
Chantry, D.3
Maini, R.4
Feldmann, M.5
-
36
-
-
0036584028
-
Development of anti-TNF therapy for rheumatoid arthritis
-
Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2(5): 364-371 (Pubitemid 37328759)
-
(2002)
Nature Reviews Immunology
, vol.2
, Issue.5
, pp. 364-371
-
-
Feldmann, M.1
-
37
-
-
47249153519
-
Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics
-
DOI 10.1111/j.1600-065X.2008.00626.x
-
Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7-19. (Pubitemid 351986171)
-
(2008)
Immunological Reviews
, vol.223
, Issue.1
, pp. 7-19
-
-
Feldmann, M.1
Maini, S.R.N.2
-
38
-
-
41949094481
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Over-view of psoriasis and guidelines of care for the treatment of psoriasis with biologics
-
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Over-view of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5): 826-850
-
(2008)
J Am Acad Dermatol
, vol.58
, Issue.5
, pp. 826-850
-
-
Menter, A.1
Gottlieb, A.2
Feldman, S.R.3
-
39
-
-
41949096736
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics
-
Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58(5): 851-864
-
(2008)
J Am Acad Dermatol
, vol.58
, Issue.5
, pp. 851-864
-
-
Gottlieb, A.1
Korman, N.J.2
Gordon, K.B.3
-
40
-
-
0035954670
-
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
-
Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345(4): 248-255
-
(2001)
N Engl J Med
, vol.345
, Issue.4
, pp. 248-255
-
-
Ellis, C.N.1
Krueger, G.G.2
-
41
-
-
0348134794
-
Treatment of Psoriasis with Alefacept: Correlation of Clinical Improvement with Reductions of Memory T-Cell Counts
-
DOI 10.1001/archderm.139.12.1563
-
Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139(12): 1563-1570 (Pubitemid 37523074)
-
(2003)
Archives of Dermatology
, vol.139
, Issue.12
, pp. 1563-1570
-
-
Gordon, K.B.1
Vaishnaw, A.K.2
O'Gorman, J.3
Haney, J.4
Menter, A.5
-
42
-
-
0036895587
-
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
-
Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47(6): 821-833
-
(2002)
J Am Acad Dermatol
, vol.47
, Issue.6
, pp. 821-833
-
-
Krueger, G.G.1
Papp, K.A.2
Stough, D.B.3
Loven, K.H.4
Gulliver, W.P.5
Ellis, C.N.6
-
43
-
-
0038385972
-
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
-
DOI 10.1001/archderm.139.6.719
-
Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebocontrolled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139(6): 719-727 (Pubitemid 36705938)
-
(2003)
Archives of Dermatology
, vol.139
, Issue.6
, pp. 719-727
-
-
Lebwohl, M.1
Christophers, E.2
Langley, R.3
Ortonne, J.P.4
Roberts, J.5
Griffiths, C.E.M.6
-
44
-
-
29244464655
-
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
-
DOI 10.1016/j.jaad.2005.10.006, PII S0190962205032330
-
Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006; 54(1): 61-63 (Pubitemid 41832458)
-
(2006)
Journal of the American Academy of Dermatology
, vol.54
, Issue.1
, pp. 61-63
-
-
Menter, A.1
Cather, J.C.2
Baker, D.3
Farber, H.F.4
Lebwohl, M.5
Darif, M.6
-
45
-
-
0345107256
-
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
-
DOI 10.1056/NEJMoa030002
-
Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349(21): 2004-2013 (Pubitemid 37448923)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.21
, pp. 2004-2013
-
-
Lebwohl, M.1
Tyring, S.K.2
Hamilton, T.K.3
Toth, D.4
Glazer, S.5
Tawfik, N.H.6
Walicke, P.7
Dummer, W.8
Wang, X.9
Garovoy, M.R.10
Pariser, D.11
-
46
-
-
17144388751
-
Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
-
Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52(3 Pt 1): 425-433
-
(2005)
J Am Acad Dermatol
, vol.52
, Issue.3 PART 1
, pp. 425-433
-
-
Leonardi, C.L.1
Papp, K.A.2
Gordon, K.B.3
-
47
-
-
42049083573
-
Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis
-
Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008; 158(5): 1107-1116
-
(2008)
Br J Dermatol
, vol.158
, Issue.5
, pp. 1107-1116
-
-
Leonardi, C.1
Menter, A.2
Hamilton, T.3
Caro, I.4
Xing, B.5
Gottlieb, A.B.6
-
48
-
-
32544441226
-
Relapse, rebound, and psoriasis adverse events: An advisory group report
-
DOI 10.1016/j.jaad.2005.10.029, PII S0190962205033165
-
Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol 2006; 54(4 Suppl 1): S171-81. (Pubitemid 43238300)
-
(2006)
Journal of the American Academy of Dermatology
, vol.54
, Issue.4 SUPPL.
-
-
Carey, W.1
Glazer, S.2
Gottlieb, A.B.3
Lebwohl, M.4
Leonardi, C.5
Menter, A.6
Papp, K.7
Rundle, A.C.8
Toth, D.9
-
49
-
-
0034729950
-
Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
-
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356(9227): 385-390 (Pubitemid 30487495)
-
(2000)
Lancet
, vol.356
, Issue.9227
, pp. 385-390
-
-
Mease, P.J.1
Goffe, B.S.2
Metz, J.3
Vanderstoep, A.4
Finck, B.5
Burge, D.J.6
-
50
-
-
10744221697
-
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
-
DOI 10.1001/archderm.139.12.1627
-
Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139(12): 1627-1632 (Pubitemid 37523083)
-
(2003)
Archives of Dermatology
, vol.139
, Issue.12
, pp. 1627-1632
-
-
Gottlieb, A.B.1
Matheson, R.T.2
Lowe, N.3
Krueger, G.G.4
Kang, S.5
Goffe, B.S.6
Gaspari, A.A.7
Ling, M.8
Weinstein, G.D.9
Nayak, A.10
Gordon, K.B.11
Zitnik, R.12
Naldi, L.13
-
51
-
-
21644481166
-
A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
-
DOI 10.1111/j.1365-2133.2005.06688.x
-
Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152(6): 1304-1312 (Pubitemid 40933433)
-
(2005)
British Journal of Dermatology
, vol.152
, Issue.6
, pp. 1304-1312
-
-
Papp, K.A.1
Tyring, S.2
Lahfa, M.3
Prinz, J.4
Griffiths, C.E.M.5
Nakanishi, A.M.6
Zitnik, R.7
Van De Kerkhof, P.C.M.8
-
52
-
-
32644437923
-
Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database
-
Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54(3 Suppl 2): S92-100.
-
(2006)
J Am Acad Dermatol
, vol.54
, Issue.3 SUPPL. 2
-
-
Gottlieb, A.B.1
Leonardi, C.L.2
Goffe, B.S.3
-
53
-
-
0037234032
-
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
-
DOI 10.1067/mjd.2003.10
-
Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48(1): 68-75. (Pubitemid 36091536)
-
(2003)
Journal of the American Academy of Dermatology
, vol.48
, Issue.1
, pp. 68-75
-
-
Gottlieb, A.B.1
Masud, S.2
Ramamurthi, R.3
Abdulghani, A.4
Romano, P.5
Chaudhari, U.6
Dooley, L.T.7
Fasanmade, A.A.8
Wagner, C.L.9
-
54
-
-
20244376625
-
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
-
DOI 10.1002/art.20967
-
Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52(4):1227-1236 (Pubitemid 40530131)
-
(2005)
Arthritis and Rheumatism
, vol.52
, Issue.4
, pp. 1227-1236
-
-
Antoni, C.E.1
Kavanaugh, A.2
Kirkham, B.3
Tutuncu, Z.4
Burmester, G.R.5
Schneider, U.6
Furst, D.E.7
Molitor, J.8
Keystone, E.9
Gladman, D.10
Manger, B.11
Wassenberg, S.12
Weier, R.13
Wallace, D.J.14
Weisman, M.H.15
Kalden, J.R.16
Smolen, J.17
-
55
-
-
4644327125
-
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
-
DOI 10.1016/j.jaad.2004.02.021, PII S019096220400742X
-
Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51(4): 534-542 (Pubitemid 39278071)
-
(2004)
Journal of the American Academy of Dermatology
, vol.51
, Issue.4
, pp. 534-542
-
-
Gottlieb, A.B.1
Evans, R.2
Li, S.3
Dooley, L.T.4
Guzzo, C.A.5
Baker, D.6
Bala, M.7
Marano, C.W.8
Menter, A.9
-
56
-
-
26644433889
-
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial
-
DOI 10.1016/S0140-6736(05)67566-6, PII S0140673605675666
-
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005; 366(9494): 1367-1374 (Pubitemid 41443403)
-
(2005)
Lancet
, vol.366
, Issue.9494
, pp. 1367-1374
-
-
Reich, K.1
Nestle, F.O.2
Papp, K.3
Ortonne, J.-P.4
Evans, R.5
Guzzo, C.6
Li, S.7
Dooley, L.T.8
Griffiths, C.E.M.9
-
57
-
-
26844432745
-
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial
-
DOI 10.1002/art.21306
-
Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52(10): 3279-3289 (Pubitemid 41447111)
-
(2005)
Arthritis and Rheumatism
, vol.52
, Issue.10
, pp. 3279-3289
-
-
Mease, P.J.1
Gladman, D.D.2
Ritchlin, C.T.3
Ruderman, E.M.4
Steinfeld, S.D.5
Choy, E.H.S.6
Sharp, J.T.7
Ory, P.A.8
Perdok, R.J.9
Weinberg, M.A.10
-
58
-
-
37349003068
-
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
-
DOI 10.1016/j.jaad.2007.09.010, PII S0190962207014375
-
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2007; 58(1): 106-115 (Pubitemid 350298146)
-
(2008)
Journal of the American Academy of Dermatology
, vol.58
, Issue.1
, pp. 106-115
-
-
Menter, A.1
Tyring, S.K.2
Gordon, K.3
Kimball, A.B.4
Leonardi, C.L.5
Langley, R.G.6
Strober, B.E.7
Kaul, M.8
Gu, Y.9
Okun, M.10
Papp, K.11
-
59
-
-
39049143819
-
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
-
DOI 10.1111/j.1365-2133.2007.08315.x
-
Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158(3): 558-566 (Pubitemid 351239154)
-
(2008)
British Journal of Dermatology
, vol.158
, Issue.3
, pp. 558-566
-
-
Saurat, J.-H.1
Stingl, G.2
Dubertret, L.3
Papp, K.4
Langley, R.G.5
Ortonne, J.-P.6
Unnebrink, K.7
Kaul, M.8
Camez, A.9
-
60
-
-
0037292855
-
Infection complications associated with the use of biologic agents
-
DOI 10.1016/S0889-857X(02)00101-1, PII S0889857X02001011
-
Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29(1): 185-202. (Pubitemid 36298110)
-
(2003)
Rheumatic Disease Clinics of North America
, vol.29
, Issue.1
, pp. 185-202
-
-
Bresnihan, B.1
Cunnane, G.2
-
61
-
-
57649220625
-
Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: A report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians
-
Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: A report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160(1): 8-15.
-
(2009)
Br J Dermatol
, vol.160
, Issue.1
, pp. 8-15
-
-
Perlmutter, A.1
Mittal, A.2
Menter, A.3
-
62
-
-
0037532694
-
Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [6]
-
DOI 10.1136/ard.62.7.686
-
Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62(7): 686-687 (Pubitemid 36760576)
-
(2003)
Annals of the Rheumatic Diseases
, vol.62
, Issue.7
, pp. 686-687
-
-
Ostuni, P.1
Botsios, C.2
Punzi, L.3
Sfriso, P.4
Todesco, S.5
-
63
-
-
0037116836
-
Drug-induced systemic lupus erythematosus associated with etanercept therapy
-
DOI 10.1016/S0140-6736(02)07714-0
-
Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359(9306): 579-580 (Pubitemid 34178442)
-
(2002)
Lancet
, vol.359
, Issue.9306
, pp. 579-580
-
-
Shakoor, N.1
Michalska, M.2
Harris, C.A.3
Block, J.A.4
-
64
-
-
19644364586
-
The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel
-
Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005; 34(6): 819-836
-
(2005)
Semin Arthritis Rheum
, vol.34
, Issue.6
, pp. 819-836
-
-
Hochberg, M.C.1
Lebwohl, M.G.2
Plevy, S.E.3
Hobbs, K.F.4
Yocum, D.E.5
-
65
-
-
43449094043
-
Ustekinumab for chronic plaque psoriasis
-
Bartlett BL, Tyring S.K. Ustekinumab for chronic plaque psoriasis. Lancet 2008; 371(9625): 1639-1640
-
(2008)
Lancet
, vol.371
, Issue.9625
, pp. 1639-1640
-
-
Bartlett, B.L.1
Tyring, S.K.2
-
66
-
-
43449111187
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
DOI 10.1016/S0140-6736(08)60725-4, PII S0140673608607254
-
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371(9625): 1665-1674 (Pubitemid 351671883)
-
(2008)
The Lancet
, vol.371
, Issue.9625
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
Yeilding, N.4
Guzzo, C.5
Wang, Y.6
Li, S.7
Dooley, L.T.8
Gordon, K.B.9
-
67
-
-
43449139402
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
-
DOI 10.1016/S0140-6736(08)60726-6, PII S0140673608607266
-
Papp KA, Langley RG, Lebwohl M, et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371(9625): 1675-1684 (Pubitemid 351671884)
-
(2008)
The Lancet
, vol.371
, Issue.9625
, pp. 1675-1684
-
-
Papp, K.A.1
Langley, R.G.2
Lebwohl, M.3
Krueger, G.G.4
Szapary, P.5
Yeilding, N.6
Guzzo, C.7
Hsu, M.-C.8
Wang, Y.9
Li, S.10
Dooley, L.T.11
Reich, K.12
-
68
-
-
70449712998
-
Ustekinumab in the therapy of chronic plaque psoriasis
-
O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 2009; 3: 159-168
-
(2009)
Biologics
, vol.3
, pp. 159-168
-
-
O'Neill, J.L.1
Kalb, R.E.2
-
69
-
-
33750390154
-
Immune therapies of autoimmune diseases: Are we approaching a real cure?
-
Chatenoud L. Immune therapies of autoimmune diseases: are we approaching a real cure? Curr Opin Immunol 2006; 18(6): 710-717
-
(2006)
Curr Opin Immunol
, vol.18
, Issue.6
, pp. 710-717
-
-
Chatenoud, L.1
-
70
-
-
41649084155
-
At the horizon of innovative therapy in rheumatology: New biologic agents
-
Finckh A, Gabay C. At the horizon of innovative therapy in rheumatology: New biologic agents. Curr Opin Rheumatol 2008; 20(3): 269-275
-
(2008)
Curr Opin Rheumatol
, vol.20
, Issue.3
, pp. 269-275
-
-
Finckh, A.1
Gabay, C.2
-
71
-
-
41549158609
-
Cytokines as therapeutic targets: Advances and limitations
-
Scheinecker C, Redlich K, Smolen JS. Cytokines as therapeutic targets: Advances and limitations. Immunity 2008; 28(4): 440-444
-
(2008)
Immunity
, vol.28
, Issue.4
, pp. 440-444
-
-
Scheinecker, C.1
Redlich, K.2
Smolen, J.S.3
-
72
-
-
0028143211
-
Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
-
Elliott MJ, R.N. Maini, M. Feldmann, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344(8930): 1105-1110
-
(1994)
Lancet
, vol.344
, Issue.8930
, pp. 1105-1110
-
-
Elliott, M.J.1
Maini, R.N.2
Feldmann, M.3
-
73
-
-
18644385243
-
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
-
DOI 10.1084/jem.20050473
-
Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201(9): 1479-1486 (Pubitemid 40664091)
-
(2005)
Journal of Experimental Medicine
, vol.201
, Issue.9
, pp. 1479-1486
-
-
Pascual, V.1
Allantaz, F.2
Arce, E.3
Punaro, M.4
Banchereau, J.5
-
74
-
-
42049120937
-
New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra
-
González-López MA, Martínez-Taboada VM, González-Vela MC, Fernández-Llaca H, Val-Bernal JF. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 2008; 158(5): 1146-1148
-
(2008)
Br J Dermatol
, vol.158
, Issue.5
, pp. 1146-1148
-
-
González-López, M.A.1
Martínez-Taboada, V.M.2
González-Vela, M.C.3
Fernández-Llaca, H.4
Val-Bernal, J.F.5
-
75
-
-
34447300492
-
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
-
DOI 10.1136/ard.2006.068064
-
Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66(9): 1162-1167 (Pubitemid 47309731)
-
(2007)
Annals of the Rheumatic Diseases
, vol.66
, Issue.9
, pp. 1162-1167
-
-
Nishimoto, N.1
Hashimoto, J.2
Miyasaka, N.3
Yamamoto, K.4
Kawai, S.5
Takeuchi, T.6
Murata, N.7
Van Heijde, D.D.8
Kishimoto, T.9
-
76
-
-
54949150604
-
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
-
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58(10): 2968-2980
-
(2008)
Arthritis Rheum
, vol.58
, Issue.10
, pp. 2968-2980
-
-
Genovese, M.C.1
McKay, J.D.2
Nasonov, E.L.3
-
77
-
-
25444519432
-
Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study
-
DOI 10.1002/art.21249
-
Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum 2005; 52(9): 2686-2692 (Pubitemid 41369096)
-
(2005)
Arthritis and Rheumatism
, vol.52
, Issue.9
, pp. 2686-2692
-
-
Baslund, B.1
Tvede, N.2
Danneskiold-Samsoe, B.3
Larsson, P.4
Panayi, G.5
Petersen, J.6
Petersen, L.J.7
Beurskens, F.J.M.8
Schuurman, J.9
Van De Winkel, J.G.J.10
Parren, P.W.H.I.11
Gracie, J.A.12
Jongbloed, S.13
Liew, F.Y.14
McInnes, I.B.15
-
78
-
-
29844440963
-
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial
-
DOI 10.1016/S0140-6736(05)67763-X, PII S014067360567763X
-
Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367(9504): 29-35. (Pubitemid 43038667)
-
(2006)
Lancet
, vol.367
, Issue.9504
, pp. 29-35
-
-
Tyring, S.1
Gottlieb, A.2
Papp, K.3
Gordon, K.4
Leonardi, C.5
Wang, A.6
Lalla, D.7
Woolley, M.8
Jahreis, A.9
Zitnik, R.10
Cella, D.11
Krishnan, R.12
|